NHAS
Novo Holdings A/S Portfolio holdings
AUM
$1.42B
This Quarter Return
+5.32%
1 Year Return
+12.08%
3 Year Return
+99.82%
5 Year Return
+98.46%
10 Year Return
+612.59%
AUM
$1.6B
AUM Growth
+$1.6B
(-24%)
Cap. Flow
-$505M
Cap. Flow
% of AUM
-31.55%
Top 10 Holdings %
Top 10 Hldgs %
54.93%
Holding
55
New
3
Increased
15
Reduced
5
Closed
7
Top Buys
| 1 |
Disc Medicine
IRON
|
$46.6M |
| 2 |
SGEN
Seagen Inc. Common Stock
SGEN
|
$17.3M |
| 3 |
DICE
DICE Therapeutics, Inc. Common Stock
DICE
|
$14.5M |
| 4 |
BLU
BELLUS Health Inc.
BLU
|
$14M |
| 5 |
Rallybio
RLYB
|
$10.9M |
Top Sells
| 1 |
Vanguard Total Stock Market ETF
VTI
|
$501M |
| 2 |
Arcellx
ACLX
|
$52.9M |
| 3 |
Boston Scientific
BSX
|
$19M |
| 4 |
Milestone Pharmaceuticals
MIST
|
$18.4M |
| 5 |
UTRS
Minerva Surgical, Inc. Common Stock
UTRS
|
$17.2M |
Sector Composition
| 1 | Healthcare | 69.58% |
| 2 | Technology | 18.99% |
| 3 | Financials | 4.49% |
| 4 | Communication Services | 4.18% |
| 5 | Consumer Discretionary | 2.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Stryker
SYK
$150B
| $195M | 12.17% | 796,941 | – | – |
|
2
ASML
ASML
$292B
| $124M | 7.74% | 226,770 | – | – |
|
3
Steris
STE
$24.1B
| $86.4M | 5.39% | 467,687 | – | – |
|
4
Salesforce
CRM
$245B
| $76.7M | 4.79% | 578,500 | – | – |
|
|
CTLT
5
DELISTED
CATALENT, INC.
CTLT
| $73.5M | 4.59% | 1,632,878 | – | – |
|
6
Brookfield
BN
$98.3B
| $71.9M | 4.49% | 2,508,830 | – | – |
|
7
Corcept Therapeutics
CORT
$7.35B
| $68.6M | 4.28% | 3,377,768 +50,000 | +2% | +$1.02M |
|
8
Cable One
CABO
$909M
| $67M | 4.18% | 94,103 +14,080 | +18% | +$10M |
|
|
9
Boston Scientific
BSX
$156B
| $62.6M | 3.91% | 1,353,081 -409,861 | -23% | -$19M |
|
10
Edgewise Therapeutics
EWTX
$1.51B
| $54.3M | 3.39% | 6,071,703 | – | – |
|
11
TSMC
TSM
$1.2T
| $52.9M | 3.31% | 710,780 | – | – |
|
12
Apple
AAPL
$3.45T
| $48M | 2.99% | 369,104 -92,275 | -20% | -$12M |
|
|
13
Disc Medicine
IRON
$2.07B
| $46.6M | 2.91% | +2,340,772 | New | +$46.6M |
|
|
14
Arcellx
ACLX
$3.85B
| $46M | 2.87% | 1,484,020 -1,707,858 | -54% | -$52.9M |
|
15
Alibaba
BABA
$322B
| $44.1M | 2.75% | 500,827 | – | – |
|
16
Vaxcyte
PCVX
$4B
| $34.8M | 2.17% | 725,000 -98,705 | -12% | -$4.73M |
|
17
BioMarin Pharmaceuticals
BMRN
$11.2B
| $32.9M | 2.05% | 317,700 +200 | +0.1% | +$20.7K |
|
18
Mirum Pharmaceuticals
MIRM
$3.71B
| $32.8M | 2.05% | 1,684,193 | – | – |
|
|
VECT
19
DELISTED
VectivBio Holding AG Ordinary Shares
VECT
| $28.9M | 1.81% | 3,339,484 | – | – |
|
|
SGEN
20
DELISTED
Seagen Inc. Common Stock
SGEN
| $27M | 1.69% | 210,000 +135,000 | +180% | +$17.3M |
|
21
Alnylam Pharmaceuticals
ALNY
$58.5B
| $26.6M | 1.66% | 112,000 +12,000 | +12% | +$2.85M |
|
22
Amicus Therapeutics
FOLD
$2.34B
| $25.6M | 1.6% | 2,095,900 -4,100 | -0.2% | -$50.1K |
|
|
VERV
23
DELISTED
Verve Therapeutics
VERV
| $17.6M | 1.1% | 911,111 | – | – |
|
24
Insmed
INSM
$28.8B
| $16.8M | 1.05% | 840,000 +70,000 | +9% | +$1.4M |
|
25
Rocket Pharmaceuticals
RCKT
$354M
| $16.6M | 1.04% | 850,000 +217,178 | +34% | +$4.25M |
|